OS-01

OS-01 – Benefits & Side Effects

OS-01 – Protocol

OS-01 – Lifestyle Considerations

Proper Peptide Storage

Why Proper Peptide Storage Matters

Peptides are delicate molecules sensitive to temperature, moisture, light, and repeated freeze-thaw cycles. Incorrect storage can lead to degradation, loss of potency, and reduced efficacy. Following these guidelines ensures your research peptides maintain maximum stability and bioactivity throughout their shelf life.

Lyophilized (Powder) Peptides

Optimal Storage:

• Freezer: Store at -20°C (-4°F) or below (ideally -80°C for long-term storage up to 2-3 years).
• Short-term: Refrigerate at 2-8°C (35.6-46.4°F) for weeks to months.
• Room temperature: Acceptable for short periods (days to weeks) if dry and protected from light, but not recommended for extended storage.
• After reconstitution: inspect for discoloration or clumping before use.

Key Practices:

• Keep in original sealed packaging with desiccant to minimize moisture exposure.
• Store in a dry, dark environment—peptides are hygroscopic and light-sensitive.
• Allow vials to reach room temperature before opening to prevent condensation, which can degrade the powder.

Reconstituted (Liquid) Peptides

Refrigeration is Essential:

• Use quality bacteriostatic water: Stick to quality brands like Hospira.
• Store at 2-8°C (35.6-46.4°F) immediately after reconstitution.
• Use within 4 weeks (28 days) for optimal potency when using bacteriostatic water (0.9% benzyl alcohol).
• Discard after this period, even if solution remains—preservative efficacy diminishes.

Important Warnings:

• Do NOT freeze reconstituted solutions—freezing denatures peptides.
• Avoid freeze-thaw cycles—they cause irreversible degradation. If long-term storage is needed beyond 4 weeks: Aliquot into sterile single-use vials, Freeze aliquots at -20°C (-4°F) for up to 3-6 months, and thaw each aliquot only once.

Handling Peptides Best Practices

1. Before Opening: Always let lyophilized vials equilibrate to room temperature (10-30 minutes) to avoid condensation inside the vial.
2. Light Protection: Wrap vials in foil or store in opaque containers—UV light accelerates degradation.
3. Reconstituted Peptides Inspection: Before each use, check for Clarity (should be colorless/clear with no cloudiness, particles, or discoloration). Discard if any issues observed.
4. Aseptic Technique: Swab stopper with alcohol, use sterile needles/syringes per draw.
5. Labeling: Mark reconstitution date on vials.

Common Peptide Storage Mistakes to Avoid

• Moisture Exposure: Never store open vials; always reseal tightly.
• Temperature Fluctuations: Avoid door storage in fridge/freezer.
• Heat/Light: Keep away from direct sunlight, heaters, or lab lights.
• Overuse of Multi-Dose Vials: Follow 28-day rule per USP/CDC guidelines.
• Freezing Liquids: Repeated cycles can reduce potency by 25%+ per cycle.

Special Peptide Considerations

• Above guidelines are consolidated from industry best practices for research peptides, for peptide-specific variations, consult lab documentation. Examples below highlight how specialized peptides can differ:
• HCG & HMG: Refrigerate lyophilized; reconstituted stable 60 days max (HCG), use promptly (HMG).
• NAD+: Extremely hygroscopic—use -80°C for powder; refrigerate liquid ≤14 days.
• PT-141: Room temp stable short-term; refrigerate reconstituted ≤1 week.

Subcutaneous Peptide Injection Protocol

Subcutaneous Peptide Injection Protocol Overview

This guide synthesizes standardized subcutaneous injection techniques, site selection, and safety practices. Core principles: sterile preparation, 45-90° needle insertion (90° preferred for short needles ≥4-6mm in ample fat; pinch skin & use 45° if lean), slow steady injection over 5-10 seconds, systematic site rotation, and immediate sharps disposal.

Preparation & Supplies

• Hand Hygiene: Wash thoroughly with soap and water.
• Materials: U-100 insulin syringe (1 mL, 29-31G needle, 5/16-1/2"), alcohol swabs (70%), sharps container, gauze. Use 30-50 unit syringes for volumes <10 units.
• Vial Prep: Wipe stopper, dry 10-30 seconds, draw dose, tap out air bubbles. Warm vials to room temperature to reduce stinging.
• Volume Limit: ≤1.5 mL per site; split larger doses (e.g., 75 IU into 3x25 IU). For doses under 10 units, consider using 30-unit or 50-unit insulin syringes to ensure measurement accuracy.

Site Selection & Rotation

Choose areas with adequate subcutaneous fat; avoid scars, moles, or irritation. Systematically rotate sites 1-1.5 inches apart; avoid same spot for 1-2 weeks. Log sites to prevent lipohypertrophy/lumping:

• Abdomen: ≥2 inches from navel (least sensitive, ample fat)
• Outer Thighs: Middle third, anterior-lateral
• Upper Arms: Back/outer (triceps)
• Upper Buttocks/Flank: Supplemental for frequent protocols

Peptide Injection Technique

Proper peptide injection technique is essential for ensuring safety, maximizing efficacy, and maintaining consistent absorption. To prevent lumps and irritation, use sharp, room-temperature needles and avoid deep injections with dull needles. Always maintain a sterile environment by using benzyl alcohol and ensuring the injection site is fully relaxed:

1. Clean site outward in circles; air-dry 30 seconds.
2. Pinch 1-2 inch skin fold to lift subcutaneous layer.
3. Insert needle at 45-90° angle (90° for ample fat, 45° for lean/thin needle).
4. No aspiration (pulling back plunger to check for blood)
5. Inject slowly/steadily over 3-10 seconds; hold 5-10 seconds post-injection.
6. Withdraw at same angle; gentle pressure if bleeding.
7. Dispose in sharps container immediately; never recap.
8. Discard any reconstituted solution if it becomes cloudy. Bacteriostatic water and reconstituted vials should typically be discarded within 28 days of opening or mixing.

Peptide Injection Timing Consideration

• Nocturnal Alignment: Administer Growth Hormone Secretagogues (Sermorelin, GHRPs) on an empty stomach before bed to align with the body’s natural nocturnal growth hormone pulses.
• Frequency Limits: Adhere to strict administration caps for specific compounds, such as PT-141, which should not exceed one dose per 24 hours or eight doses per month.
• Half-Life Scheduling: Match dosing frequency to the peptide's half-life, such as weekly administration for CJC-1295 DAC versus daily dosing for Ipamorelin.
• Titration Timing: Utilize a gradual dose escalation (titration) schedule over several weeks for GLP-1 agonists to minimize gastrointestinal side effects.
• Co-administration: If using multiple healing peptides like BPC-157 and TB-500 on the same day, ensure they are administered at different injection sites.
• Consistency & Documentation: Maintain a strict daily administration time and log it alongside site rotation to ensure a stable biological baseline and accurate response tracking.

Peptide Post-Injection Care & Risks

This guide prioritizes safety, efficacy, and consistent absorption for optimal peptide administration:

• Monitor for redness/swelling; rest site 1-7 days if severe.
• No massage (disrupts absorption).
• Document dose, site, time, reactions.
• Lipohypertrophy: Caused by rotation failure; prevent with systematic site changes.
• Pain/Lumps: From deep injection, cold solution, or dull needles.
• Infection: Maintain asepsis; monitor for fever/redness.

OS-01 – Identification

Chemical Properties

Common Name(s): OS-01, Peptide 14, Peptide OS-01, Decapeptide-52, O-304

CAS Number: 1261289-04-6

Molecular Formula: C₁₆H₁₁Cl₂N₃O₂S

Molecular Weight: 380.2 Da

Amino Acid Sequence: Not publicly disclosed in peer-reviewed literature; proprietary composition protected by OneSkin Technologies patent portfolio; described only as a 10-amino acid (decapeptide) or 14-amino acid sequence depending on formulation variant

Structural Characteristics: Linear peptide; contains chlorine residues in structure (unusual for standard amino acid-based peptides, suggesting potential non-standard amino acids or chemical modifications); exact three-dimensional conformation not disclosed

Administration Route: Topical (in commercial skincare formulations); oral administration tested in research contexts; potential for systemic delivery (subcutaneous, intraperitoneal) in preclinical studies

Origin & Type Classification

Source: Synthetic; designed through rational drug discovery specifically to activate AMPK without requiring AMP-dependent mechanisms

Biosynthesis: Laboratory-synthesized using chemical peptide synthesis methods; not derived from natural peptides or proteins

Functional Class: Senomorphic peptide; AMPK activator; metabolic regulator; cellular aging modifier

Structural Type: Linear peptide (10 or 14 amino acids depending on formulation variant)

Salt Form(s): Formulations may include various salt forms depending on commercial product design; typically incorporated into topical vehicles with humectants (glycerin, hyaluronic acid), emollients (oils, butters), and botanical extracts

Stability: OS-01 demonstrates stability in topical formulations at room temperature; resistant to degradation in presence of common skincare ingredients and preservatives

Mechanism of Action

Primary Target: 5' AMP-activated protein kinase (AMPK), a heterotrimeric enzyme complex with 12 known isoforms in humans

Activation Mechanism: AMP-independent AMPK activator; suppresses dephosphorylation of p-T172 (phosphorylated threonine 172) on AMPK-alpha catalytic subunit, extending AMPK's active (phosphorylated) state duration

Downstream Effects:

• Upregulation of PGC-1α, master regulator of mitochondrial biogenesis

• Activation of autophagy, particularly mitophagy (selective mitochondrial autophagy)

• Upregulation of antioxidant genes SOD2 and catalase

• Increased glucose uptake in skeletal muscle

• Enhancement of fatty acid oxidation

• Inhibition of cholesterol, fat, and triglyceride synthesis

Database References

• PubChem CID: 50923806

• ChemicalBook: Listed under AMPK activators

• UniProt: AMPK-alpha and beta/gamma regulatory subunits

• NCBI: Genetic and literature resources for AMPK signaling

• PDB: AMPK complex structural information available

Note: OS-01 is a proprietary peptide with limited chemical disclosure in peer-reviewed literature. Complete amino acid sequence and exact structural modifications remain protected intellectual property. Commercial formulations may vary in OS-01 concentration and co-formulated ingredients.

OS-01 – Research

Study: Double-blind, vehicle-controlled clinical investigation of peptide OS-01 (pDPK) for skin health
Benefits: Locks in moisture, cuts wrinkles round eyes, boosts glow and texture.
Link: https://pubmed.ncbi.nlm.nih.gov/38400612/
Summary: OS-01, mitophagy trigger (cleans old cell parts), in cream. 12-week face-half trial, 22 people: OS-01 side sealed water loss better, wrinkles eased (3D scans), texture/radiance up big. Both sides helped but OS-01 superior. Old cells cleared for fresh skin. Like house spring clean: smoother, dewier face for teen glow-up.

Study: Clinical efficacy of OS-01 peptide formulation in reducing the signs of aging in the periorbital region
Benefits: 17% less water loss, 32% hydration jump, 25% elasticity gain, fades puff/dark circles.
Link: https://pubmed.ncbi.nlm.nih.gov/39788697/
Summary: Eye cream trial 12 weeks: TEWL down 17%, hydration +32%, firmness +10%, bounce +25%. Lines/puff/circles shrunk; 95% saw better look. Safe powerhouse for tired eyes from screens/sleep.

Study: OS-01 Peptide Topical Formulation Improves Skin Barrier Function
Benefits: Strengthens barrier vs. dryness, radiance boost, anti-senescence cleanup.
Link: https://pubmed.ncbi.nlm.nih.gov/40193112/
Summary: Builds barrier, fights dehydration/wrinkles via cell refresh. Youthful skin sans irritation.

OS-01 – Research Links